Incidence

Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19

Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patient, U.S. Department of Defense Strategy for Operating in Cyberspace, Cancer prevention, World Health Organization, CEO, Technology, Research institute, MCDC, MERS, Pandemic, Immunodeficiency, PCR, Studio, World, Army, Severe acute respiratory syndrome coronavirus 2, Virus, Severity, UT, D, Efficacy, Urinary tract infection, Infection rate, Epidemic, Cough, COVID-19, Animal, National, Cancer Prevention and Research Institute of Texas, NIAID, Medicine, ROS, Safety, Data lake, Incidence, Radiation, Reactive oxygen species, SARS, Degenerative disease, Immune system, Fannin, Command, OSCI, DOD, Fatigue, Epithelium, Pharmaceutical industry, Vaccine
Thursday, December 2, 2021 - 3:47am

Results from these trials support the potential of PUL-042 in reducing the severity of COVID-19.

Key Points: 
  • Results from these trials support the potential of PUL-042 in reducing the severity of COVID-19.
  • We now have data from over 200 subjects treated with PUL-042, said Dr. Colin Broom, CEO of Pulmotect.
  • Subjects were tested for SARS-CoV-2 using a nasopharyngeal PCR test at study enrollment and again after 15 and 28 days.
  • All three PUL-042 treated subjects cleared virus by Day 15 of the trial compared to none of the three placebo treated subjects.

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

Special, CCR3, Form, Vaccination, Prospectus, Immunity, Risk, GLOBE, Incidence, Infection, RSV, Influenza, Private Securities Litigation Reform Act, Degenerative disease, Eosinophil, Death, Research, Tripura Merger Agreement, File, T helper cell, Failure, TLR4, Interferon, Sale, Forward-looking statement, Absenteeism, Seroconversion, PETRA, NASDAQ, Business architecture, Mergers and acquisitions, FDA, Rhinovirus, Polyp, Allergic rhinitis, Securities Act of 1933, Safety, Technology, Acquisition, Severe acute respiratory syndrome coronavirus 2, SEC, Proxy, SAN, Business, Revelation, COVID-19, Nasdaq, EMA, Ownership, Name, CDC, MMID, AUC, Respiratory syncytial virus, Disease, Vaccine, Online shopping, Financial services
Wednesday, December 1, 2021 - 9:01pm

The viral challenge study is the next necessary step in clinical development of REXTx-99 for the treatment of respiratory viral infections.

Key Points: 
  • The viral challenge study is the next necessary step in clinical development of REXTx-99 for the treatment of respiratory viral infections.
  • The start of our viral challenge study is an important step in bringing a potential new therapy to bear on this problem.
  • The Phase 2b, randomized, double-blind, placebo-controlled study will enroll up to 60 participants.
  • The primary endpoint is to evaluate the efficacy of REVTx-99 in reducing influenza virus load in the upper airways during infection.

National Geographic Releases Second Season of Companion Podcast to Investigative Series TRAFFICKED WITH MARIANA VAN ZELLER

Online, Mobile, Wireless, Entertainment, Mobile Entertainment, Social Media, Internet, Technology, Other Education, General Entertainment, Education, TV and Radio, Audio, Video, Communications, Black Madam, Fast Times, Woman, Incidence, National Geographic, Special Project, Davar Ardalan, LinkedIn, Travel, Amazon, Book, Frank Meeink, DuPont, National Geographic Society, National Geographic Partners, WITH, Dream, Marguerite Young (journalist), Social media, Livingston Award, DEA, YouTube, National, NGP, Police, Pinterest, Habit, Education, Shoe, Geographer, Twitter, The Walt Disney Company, Rape, Multimedia, Television, Charlie D'Agata, PODCAST, Freezing, Hulu, National Geographic (American TV channel), Black Hills, Peabody, Heroin, Instagram, Science, THE, ATF, Fentanyl, Drug
Wednesday, December 1, 2021 - 7:30pm

Ahead of the premiere of the second season of Emmy-nominated investigative series TRAFFICKED WITH MARIANA VAN ZELLER on Wednesday, Dec. 1, at 9/8c, National Geographic announced the release of an all-new season of the series companion podcast.

Key Points: 
  • Ahead of the premiere of the second season of Emmy-nominated investigative series TRAFFICKED WITH MARIANA VAN ZELLER on Wednesday, Dec. 1, at 9/8c, National Geographic announced the release of an all-new season of the series companion podcast.
  • After each episode of the television series, award-winning journalist Mariana van Zeller delves deeper into the topics with additional new stories to get further insight into the lives of traffickers in THE TRAFFICKED PODCAST WITH MARIANA VAN ZELLER.
  • THE TRAFFICKED PODCAST WITH MARIANA VAN ZELLER is produced for National Geographic by Muck Media.
  • This podcast is a companion to TRAFFICKED WITH MARIANA VAN ZELLER on National Geographic.

Clinical Research Processes Struggle to Adapt Amidst Pandemic

Patient, Scientific American, CEO, Clinical trial, NBCUniversal Television and Streaming, Technology, NIH, Company, Vaccine, COVID-19, Child, Conditional sentence, Physician, Research, Telehealth, Incidence, Informatics, Acceleration, Omicron, McKinsey & Company, NBCNews.com, Efficiency, FDA, Ecosystem, Internet, Travel, COVID, Animal, Pharmaceutical industry, Medical device
Wednesday, December 1, 2021 - 4:20pm

The pandemic has intensified worldwide research collaboration and a reprioritization and rethinking of the process of how healthcare is delivered or received."

Key Points: 
  • The pandemic has intensified worldwide research collaboration and a reprioritization and rethinking of the process of how healthcare is delivered or received."
  • As noted, another key weapon in the battle against the pandemic is, and continues to be, an acceleration of the clinical trial process.
  • (5) Partly as a result of the COVID pandemic, says Rajasimha, significant progress is being made in improving both efficiency and diversity in clinical trials.
  • "It is, however, becoming the norm that is essential for us to ensure continuity and integrity of clinical trials," says Dr. Rajasimha.

BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category

Patient, Birth, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Candidiasis, Nausea, COVID-19 vaccine, Most, Drug of last resort, Woman, CYP3A, New Drug Application, COVID-19, Abdominal pain, Pregnancy, Security, GLOBE, Diarrhea, Incidence, Dizziness, Tablet, NDA, Biotechnology, Global health, Vaginal yeast infection, Infection, Vomiting, Administration, FDA, Fungus, Food, NASDAQ, Pharmaceutical industry, Dietary supplement
Wednesday, December 1, 2021 - 3:37pm

JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that BREXAFEMME (ibrexafungerp tablets) has been named as a Popular Science 2021 Best of Whats New award winner in the Health category.

Key Points: 
  • JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that BREXAFEMME (ibrexafungerp tablets) has been named as a Popular Science 2021 Best of Whats New award winner in the Health category.
  • Best of Whats New awards are presented to products and technologies in 10 categories: Aerospace, Automotive, Engineering, Entertainment, Gadgets, Health, Home, Personal Care, Sports & Outdoors, and Security.
  • BREXAFEMME is a novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection.
  • SCYNEXIS launched its first commercial product in the U.S., BREXAFEMME (ibrexafungerp tablets) , which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021.

South Africa Orders 60 Million Viracide™ Masks, the New SAHPRA Approved Mask Deactivates COVID-19 & Its Variants in Under One Minute of Contact

Infectious Diseases, Health, Medical Supplies, Medical Devices, Sale, Mask, Pressure, Technology, CE, BMJ, Industry, Global Partners, Drink, Vitamin, LTD, Severe acute respiratory syndrome coronavirus 2, Leadership, COVID-19, UMS, Risk, LLC, Incidence, Government, Water, US FDA, SAHPRA, FDA, Innovation, Fluid mechanics, Coronavirus, Food, Filtration, Certification, PPE, COVID, PTY, Pharmaceutical industry, Personal protective equipment
Wednesday, December 1, 2021 - 2:05pm

Today, Vitiprints LLC announced that the company received an order from South Africa for 60 million Viracide Masks.

Key Points: 
  • Today, Vitiprints LLC announced that the company received an order from South Africa for 60 million Viracide Masks.
  • South Africa is the first country to join The Viracide Deactivation Nation global campaigna call to action for countries to join together and deactivate COVID-19 by encouraging citizens to wear a Viracide Mask.
  • The disruptive technology used in Viracide Masks will help save lives by stopping the spread of COVID-19 and its variants.
  • Viracide masks can reduce the incidence to an even greater degree providing the wearer with both mask and enhanced antiviral.

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth

Audio, Video, Pharmaceutical, Telecommunications, Oncology, Software, Networks, Medical Devices, Internet, Hospitals, VoIP, Technology, Practice Management, Mobile, Wireless, Managed Care, Medical Supplies, General Health, Biotechnology, Health, Patient, Pacific Northwest, Security (finance), GERD, Cancer, Cell, Gastroenterology, Technology, Time, Esophageal cancer, Forward-looking statement, Death, Science Translational Medicine, PCP, Partnership, Diagnosis, U.S. Securities and Exchange Commission, Male, Laboratory developed test, COVID-19, Heartburn, Cyclin A1, NGS, Physician, EAC, Radio, Nasdaq, Methylation, Research, Risk, Lucid, LDT, Telehealth, Incidence, Obesity, FDA, CCNA1, Intention, Growth, CE marking, Television, Therapy, Gene, VIM, Medical imaging, Pharmaceutical industry
Wednesday, December 1, 2021 - 1:30pm

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.
  • We are fortunate to have an ideal partner in UpScriptHealth, a pioneer in online healthcare prescribing with a nationwide network of telemedicine physicians, as we look to expand the EsoGuard Telemedicine Program and Lucid Test Center network regionally and nationally.
  • Now, patients who respond to direct-to-consumer engagements can request video telemedicine evaluation through the EsoGuard Telemedicine Program by contacting 1-888-FOODTUBE or registering at www.EsoGuardConsultation.com .
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection

Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Patient, Algorithm, Pharmacokinetics, Peptide, Half-life, Biofilm, Paper, Technology, Bacteria, Cooperative, MD, Antimicrobial Agents and Chemotherapy, Doctor of Philosophy, Tolerability, Peter Thiel, Therapy, Trust law, AAC, Twitter, Research, Clinician Administered PTSD Scale, Incidence, Knee, Infection, Artificial intelligence, KNEA, Wellcome Trust, Founders Fund, Person, LinkedIn, Single, Pharmaceutical industry, Antibiotics
Wednesday, December 1, 2021 - 1:00pm

The incidence of treatment emergent adverse events (TEAE) related to PLG0206 was low and most events were mild in severity and similar between the PLG0206 treatment and placebo groups.

Key Points: 
  • The incidence of treatment emergent adverse events (TEAE) related to PLG0206 was low and most events were mild in severity and similar between the PLG0206 treatment and placebo groups.
  • The median terminal half-life ranged from 7.37 to 19.92 hours, which is significantly longer when compared to other unmodified linear peptides.
  • PLG0206 represents the untapped potential to design peptides with enhanced therapeutic characteristics, enabling medicines to become simultaneously more effective and less toxic.
  • Using proprietary peptide engineering techniques, Peptilogics has optimized PLG0206 for both safety and rapidly, bactericidal, broad-spectrum activity against biofilms that harbor and protect bacteria from most antibiotics.

When and How to Screen for Colorectal Cancer? New NCCN Patient Guideline Explains Latest Timing and Approaches

Patient, Caregiver, Ness, Death, Cancer, Doctor of Philosophy, MPH, COVID-19, Large intestine, Colorectal cancer, Physician, Journal of the National Comprehensive Cancer Network, Policy, Research, Risk, Incidence, Javi Llor, Vanderbilt-Ingram Cancer Center, Decision-making, Associate, DRS, MPPA, NCCN, CRC, National Comprehensive Cancer Network, Medical imaging, Mobile phone, Health insurance
Wednesday, December 1, 2021 - 1:37pm

PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN) today announced the publication of new NCCN Guidelines for Patients: Colorectal Cancer Screening .

Key Points: 
  • PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN) today announced the publication of new NCCN Guidelines for Patients: Colorectal Cancer Screening .
  • This new, free guide for patients and caregivers breaks down the different ways screening can be done and explains the recommended timing according to the latest research.
  • "This new patient guideline from NCCN offers a better understanding of the scientific research for the larger community.
  • Llor and Ness both stressed that patients at any age who experience symptoms should be evaluated for colorectal cancer.

When and How to Screen for Colorectal Cancer? New NCCN Patient Guideline Explains Latest Timing and Approaches

Patient, Caregiver, Ness, Death, Cancer, Doctor of Philosophy, MPH, COVID-19, Large intestine, Colorectal cancer, Physician, Journal of the National Comprehensive Cancer Network, Policy, Research, Risk, Javi Llor, Incidence, Vanderbilt-Ingram Cancer Center, Decision-making, Associate, DRS, MPPA, NCCN, CRC, National Comprehensive Cancer Network, Medical imaging, Mobile phone, Health insurance
Wednesday, December 1, 2021 - 1:37pm

PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Colorectal Cancer Screening. Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer in the United States, with an estimated 104,270 new cases of colon cancer and 43,230 new cases of rectal cancer in 2021, and an estimated 52,980 deaths this year.1 Screening can reduce the rate of death by catching CRC at an earlier, more treatable stage, and can reduce overall cancer incidences by detecting and removing pre-cancerous polyps. This new, free guide for patients and caregivers breaks down the different ways screening can be done and explains the recommended timing according to the latest research.

Key Points: 
  • PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN) today announced the publication of new NCCN Guidelines for Patients: Colorectal Cancer Screening .
  • This new, free guide for patients and caregivers breaks down the different ways screening can be done and explains the recommended timing according to the latest research.
  • "This new patient guideline from NCCN offers a better understanding of the scientific research for the larger community.
  • Llor and Ness both stressed that patients at any age who experience symptoms should be evaluated for colorectal cancer.